| ๐ท๏ธย Parameter | ๐ย Details |
|---|---|
| ๐งฌ Active Ingredient | Nevirapine |
| ๐ Indication | HIV-1 Infection (part of combination ART) |
| ๐บ๐ธ US Brand | Viramuneยฎ |
| ๐ญ Manufacturer | Cipla Limited |
| ๐ฆ Packaging | 60 tablets in 1 bottle (200 mg/tablet) |
| ๐ช Strength | 200 mg |
| ๐ Delivery Time | 7โ14 days (Worldwide) |
๐งฌ Introduction to Nevimune (Nevirapine)
Nevimune by Cipla containsย Nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV-1 treatment. As part of combination antiretroviral therapy (ART), it:
-
๐ฌ Blocks HIV reverse transcriptase enzyme
-
๐ Increases CD4 counts
-
๐ Reduces viral load
Cipla’s 60-tablet bottle ensures 30-day supply for maintenance (200mg BID after lead-in). Not recommended for post-exposure prophylaxis (PEP) due to delayed efficacy.
๐ Dosage & Indications
| ๐ย Indication | ๐งชย Dosage | โฑ๏ธย Frequency | ๐กย Notes |
|---|---|---|---|
| Adults (Initial) | 200 mg/day (14-day lead-in) | Once daily | Monitor for rash |
| Adults (Maintenance) | 200 mg BID | Twice daily | Start after lead-in |
| Children (โฅ15kg) | 150โ200 mg/mยฒ/day | Twice daily | Max 400 mg/day |
| Hepatic Impairment | Avoid in moderate-severe | Contraindicated | ALT >5ร ULN |
โ ๏ธ Side Effects, Storage & Warnings
-
โ Common Side Effects: Rash (16%), headache, nausea, fatigue.
-
๐ซ Serious Effects:
-
Stevens-Johnson Syndrome (SJS)
-
Hepatotoxicity (fatal in 1.2% of women CD4>250/mmยณ)
-
Hypersensitivity reactions
-
-
โ๏ธ Storage: 15โ30ยฐC; keep bottle tightly closed (desiccant included).
-
โ ๏ธ Warnings:
-
Contraindicated if CD4>250/mmยณ (women) or CD4>400/mmยณ (men)
-
Discontinue permanently if rash with systemic symptoms
-
Avoid in patients with HLA-DRB1*01 genotype
-
๐ Global Availability & Shipping
| ๐ย Region | ๐ฆย Shipping | ๐ตย Price (60-tablet bottle) | ๐ย Prescription |
|---|---|---|---|
| ๐บ๐ธ USA | โ Yes | $45โ$70 | Required |
| ๐ฌ๐ง UK | โ Yes | ยฃ35โยฃ60 | Required |
| ๐ฆ๐บ Australia | โ Yes | AUD 65โ100 | Required |
๐ Related Indian Alternatives (Different in Same Category)
| ๐ Product Name | ๐ญ Manufacturer | ๐ Internal Link |
|---|---|---|
| Efavir (Efavirenz) | Cipla | Efavir |
| Doluteg (Dolutegravir) | Emcure | Doluteg |
| Tenvir (Tenofovir) | Cipla | Tenvir |
| Lopimune (Lopinavir/Ritonavir) | Cipla | Lopimune |
| Viraday (Efavirenz/Emtricitabine/Tenofovir) | Cipla | Viraday |
| Abamune (Abacavir) | Cipla | Abamune |
๐ External Medical References
๐ฉบ Expert Commentary
Dr. Nisha Rao, HIV Specialist:
*”Nevimune requires strict adherence to the 14-day lead-in period to mitigate rash risks. For women with CD4>200/mmยณ, [Doluteg] (Dolutegravir) is safer. Always check HLA status โ Ciplaโs generic carries identical black-box warnings as Viramune.”*
๐ Disclaimer
This information is not medical advice. Use under physician supervision. Ciplaโs Nevimune is contraindicated in occupational exposure prophylaxis.
๐ก Clinical Protocol:
-
Rash Management:
-
Grade 1-2 (localized): Continue + antihistamines
-
Grade 3-4 (mucosal involvement):ย PERMANENT DISCONTINUATION
-
-
Liver Monitoring:
-
Baseline ALT/AST โ Repeat at 2, 4, 8 weeks
-
Discontinue if ALT >5ร ULN + symptoms
-
-
Cipla Bottle ID: White HDPE bottle with “NEVIMUNE-200” label
-
Drug Interactions:
-
โ Effectiveness of hormonal contraceptives
-
โ Methadone metabolism (monitor withdrawal)
-






